Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2014, Article ID 637969, 11 pages
http://dx.doi.org/10.1155/2014/637969
Research Article

Effect of Lianhuaqingwen Capsules on Airway Inflammation in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Department of Pneumology, Huashan Hospital, Fudan University, No. 12 Wulumuqi Zhong Road, Shanghai 200040, China

Received 23 January 2014; Revised 25 April 2014; Accepted 3 May 2014; Published 25 May 2014

Academic Editor: Kenji Watanabe

Copyright © 2014 Liang Dong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Global Strategy for Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011, http://www.goldcopd.org.
  2. Centers for Disease Control and Prevention, “Chronic obstructive pulmonary disease among adults—United States,” Morbidity and Mortality Weekly Report, vol. 61, no. 46, pp. 938–943, 2012. View at Google Scholar
  3. Y. Gong, G. C. Shi, H. Y. Wan et al., “Changes in prevalences of COPD within 5 years in people aged no less than 60 years in Shanghai urban area,” Acta of Shanghai Jiaotong University, vol. 31, no. 2, pp. 216–220, 2011. View at Google Scholar · View at Scopus
  4. E. M. Drost, K. M. Skwarski, J. Sauleda et al., “Oxidative stress and airway inflammation in severe exacerbations of COPD,” Thorax, vol. 60, no. 4, pp. 293–300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Bhowmik, T. A. Seemungal, R. J. Sapsford, and J. A. Wedzicha, “Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations,” Thorax, vol. 55, no. 2, pp. 114–120, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. C. J. Murray and A. D. Lopez, “Mortality by cause for eight regions of the world: global burden of disease study,” The Lancet, vol. 349, no. 9061, pp. 1269–1276, 1997. View at Google Scholar
  7. S. D. Sullivan, S. D. Ramsey, and T. A. Lee, “The economic burden of COPD,” Chest, vol. 117, supplement 2, pp. 5S–9S, 2000. View at Google Scholar · View at Scopus
  8. D. M. Halpin, M. Decramer, B. Celli, S. Kesten, D. Liu, and D. P. Tashkin, “Exacerbation frequency and course of COPD,” International Journal of Chronic Obstructive Pulmonary Disease, vol. 7, pp. 653–661, 2012. View at Publisher · View at Google Scholar
  9. E. Sapey and R. A. Stockley, “COPD exacerbations ·2: aetiology,” Thorax, vol. 61, no. 3, pp. 250–258, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. G. de Serres, N. Lampron, J. La Forge et al., “Importance of viral and bacterial infections in chronic obstructive pulmonary disease exacerbations,” Journal of Clinical Virology, vol. 46, no. 2, pp. 129–133, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Dimopoulos, M. Lerikou, S. Tsiodras et al., “Viral epidemiology of acute exacerbations of chronic obstructive pulmonary disease,” Pulmonary Pharmacology and Therapeutics, vol. 25, no. 1, pp. 12–18, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Miravitlles, “Exacerbations of chronic obstructive pulmonary disease: when are bacteria important?” European Respiratory Journal, Supplement, vol. 36, pp. 9s–19s, 2002. View at Google Scholar · View at Scopus
  13. S. Sethi, R. Sethi, K. Eschberger et al., “Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 176, no. 4, pp. 356–361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. P. M. Calverley, J. A. Anderson, B. Celli et al., “Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease,” The New England Journal of Medicine, vol. 356, no. 8, pp. 775–789, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Y. Liu, X. Q. Li, and S. Q. Cai, “Advances in pharmacology and clinical research of lianhuaqingwen capsules,” Pharmacology and Clinics of Chinese Materia Medica, vol. 26, no. 6, pp. 84–85, 2010. View at Google Scholar
  16. H. Y. Mo, C. W. Ke, J. P. Zheng, and N. S. Zhong, “Anti-viral effects of Lianhua Qingwen Capsule against influenza a virus in vitro,” Traditional Chinese Drug Research & Clinical Pharmacology, vol. 18, no. 1, pp. 5–9, 2007. View at Google Scholar
  17. J. Li, “Efficacy of Lianhua Qingwen Capsule on influenza combined with bronchial pneumonia,” Guang Ming Zhong Yi, vol. 26, no. 12, pp. 2450–2451, 2011. View at Google Scholar
  18. H. Guo, Q. H. Zhang, J. Ang, and J. N. Gong, “Effect of Lianhua Qingwen Capsule on T lymphocyte subpopulation of influenza viruses,” Acta of Nanjing Traditional Chinese Medicine University, vol. 23, no. 2, pp. 106–108, 2007. View at Google Scholar
  19. J. W. Xia, X. D. Chen, J. Zhang, and Z. W. Zhou, “Experimental investigation of the effect of Lianhuaqingwen Capsule on the rat models of chronic obstructive pulmonary disease,” Fudan University Journal of Medical Sciences, vol. 35, no. 3, pp. 441–444, 2008. View at Google Scholar · View at Scopus
  20. E. R. Sutherland, J. Pak, E. L. Langmack, P. E. Silkoff, and R. J. Martin, “Safety of sputum induction in moderate-to-severe chronic obstructive pulmonary disease,” Respiratory Medicine, vol. 96, no. 7, pp. 482–486, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Bathoorn, J. Liesker, D. Postma, G. Koeter, A. J. van Oosterhout, and H. A. Kerstjens, “Safety of sputum induction during exacerbations of COPD,” Chest, vol. 131, no. 2, pp. 432–438, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Agusti, J. J. Soler, J. Molina et al., “Is the CAT questionnaire sensitive to changes in health status in patients with severe COPD exacerbations?” Journal of Chronic Obstructive Pulmonary Disease, vol. 9, no. 5, pp. 492–498, 2012. View at Publisher · View at Google Scholar
  23. S. D. Aaron, J. B. Angel, M. Lunau et al., “Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 2, pp. 349–355, 2001. View at Google Scholar · View at Scopus
  24. C. Moermans, V. Heinen, M. Nguyen et al., “Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease,” Cytokine, vol. 56, no. 2, pp. 298–304, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Mukhopadhyay, J. R. Hoidal, and T. K. Mukherjee, “Role of TNFalpha in pulmonary pathophysiology,” Respiratory Research, vol. 7, article 125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Mukaida, “Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases,” The American Journal of Physiology: Lung Cellular and Molecular Physiology, vol. 284, no. 4, pp. L566–L577, 2003. View at Google Scholar · View at Scopus
  27. K. Fujimoto, M. Yasuo, K. Urushibata, M. Hanaoka, T. Koizumi, and K. Kubo, “Airway inflammation during stable and acutely exacerbated chronic obstructive pulmonary disease,” European Respiratory Journal, vol. 25, no. 4, pp. 640–646, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. R. Hurst, W. R. Perera, T. M. A. Wilkinson, G. C. Donaldson, and J. A. Wedzicha, “Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease,” The American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 1, pp. 71–78, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Rohde, I. Borg, A. Wiethege et al., “Inflammatory response in acute viral exacerbations of COPD,” Infection, vol. 36, no. 5, pp. 427–433, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Almansa, M. Sanchez-Garcia, A. Herrero et al., “Host response cytokine signatures in viral and nonviral acute exacerbations of chronic obstructive pulmonary disease,” Journal of Interferon and Cytokine Research, vol. 31, no. 5, pp. 409–413, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. V. M. Pinto-Plata, G. Livnat, M. Girish et al., “Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD,” Chest, vol. 131, no. 1, pp. 37–43, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. K. H. Groenewegen, M. A. Dentener, and E. F. M. Wouters, “Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD,” Respiratory Medicine, vol. 101, no. 11, pp. 2409–2415, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. P. J. Barnes, S. D. Shapiro, and R. A. Pauwels, “Chronic obstructive pulmonary disease: molecular and cellular mechanisms,” European Respiratory Journal, vol. 22, no. 4, pp. 672–688, 2003. View at Google Scholar · View at Scopus
  34. F. Kheradmand, M. Shan, C. Xu, and D. B. Corry, “Autoimmunity in chronic obstructive pulmonary disease: clinical and experimental evidence,” Expert Review of Clinical Immunology, vol. 8, no. 3, pp. 285–292, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. B. M. Vanaudenaerde, S. E. Verleden, R. Vos et al., “Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders,” The American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 8, pp. 977–986, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. Q. Wu, R. J. Martin, J. G. Rino, R. Breed, R. M. Torres, and H. W. Chu, “IL-23-dependent IL-17 production is essential in neutrophil recruitment and activity in mouse lung defense against respiratory Mycoplasma pneumoniae infection,” Microbes and Infection, vol. 9, no. 1, pp. 78–86, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. A. di Stefano, G. Caramori, I. Gnemmi et al., “T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients,” Clinical and Experimental Immunology, vol. 157, no. 2, pp. 316–324, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Zhang, S. Chu, X. Zhong, Q. Lao, Z. He, and Y. Liang, “Increased expression of CD4+IL-17+ cells in the lung tissue of patients with stable chronic obstructive pulmonary disease (COPD) and smokers,” International Immunopharmacology, vol. 15, no. 1, pp. 58–66, 2013. View at Publisher · View at Google Scholar
  39. M. Cazzola and M. G. Matera, “IL-17 in chronic obstructive pulmonary disease,” Expert Review of Respiratory Medicine, vol. 6, no. 2, pp. 135–138, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. N. J. Wilson, K. Boniface, J. R. Chan et al., “Development, cytokine profile and function of human interleukin 17-producing helper T cells,” Nature Immunology, vol. 8, no. 9, pp. 950–957, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. C. L. Langrish, Y. Chen, W. M. Blumenschein et al., “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation,” Journal of Experimental Medicine, vol. 201, no. 2, pp. 233–240, 2005. View at Google Scholar